Study details
Enrolling now
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Eli Lilly and Company
NCT IDNCT07426380ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Ages
18–85
Locations
2 sites in FL
What this study is about
This Phase 1 study is focused on people with end stage kidney disease. The primary outcome being measured is PK: Maximum Observed Drug Concentration (Cmax) of LY3841136.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: PK: Maximum Observed Drug Concentration (Cmax) of LY3841136, Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity AUC(0-∞) of LY3841136
Body systems
Renal